As two NCI-designated comprehensive cancer centers that were collaborative as prior UOl sites, the University of Wisconsin Carbone Cancer Center (UWCCC) and Rutgers Cancer Institute of New Jersey (CINJ) have proven leadership, a robust infrastructure, and a strong record of conducting clinical trials collaboratively. UWCCC and CINJ have, therefore, formed the Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics (WIN-Alliance) with a mission to develop and evaluate innovative early phase experimental therapeutic clinical trials in a multi-disciplinary and multi-institutiona model. Scientific strengths include a translational emphasis with biomarker development; pharmacogenomic assessment; genomic assessment and treatment; clinical and tissue imaging; and systems biology. Organizationally, we have formed working groups that leverage scientific expertise and infrastructural strengths from center shared resources to prioritize ET-CTN efforts. Specific niches unique to the WIN-Alliance include strong PK/PD efforts at UWCCC already adding value to CTEP/U01 clinical trials; complementary imaging strengths at UWCCC and CINJ; genomic analysis using the Rutgers University Cell and DNA Repository (RUCDR); and CINJ's relationship with the Institute for Advanced Study's Simons Center for Systems Biology. Over the past five-years UWCCC and CINJ accrued over 4,000 patients on all therapeutic trials, developed 67 center science driven proposals to NCI-CTEP, and accrued a mean of the targeted 100 patients/yr to the UOl supported studies.
The specific aims are to: 1) develop and perform early clinical trials with new ET-CTN sponsored anti-cancer agents; 2) leverage and synergize with center programmatic areas of research and cores to translate scientific discoveries from the laboratory into clinical trials; 3) develop integrated and integral genomic, pharmacogenomics, pharmacokinetic, and pharmacodynamic biomarkers; 4) develop integral and integrated novel approaches to clinical and tissue imaging; and, 5) train and develop young investigators in translational research.

Public Health Relevance

This application will merge two strong prior Phase I (UOl) sites to create the Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics (WIN-Alliance). This group, as a synergistic, multidisciplinary and multi-institutional model, will develop and evaluate innovative, early phase experimental therapeutic clinical trials to improve clinical outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1CA186716-04
Application #
9293981
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ivy, S Percy
Project Start
2014-03-19
Project End
2020-02-29
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
Overall Medical
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
Bommareddy, Praveen K; Silk, Ann W; Kaufman, Howard L (2017) Intratumoral Approaches for the Treatment of Melanoma. Cancer J 23:40-47
Mehnert, Janice M; Monjazeb, Arta M; Beerthuijzen, Johanna M T et al. (2017) The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clin Cancer Res 23:4970-4979
Bommareddy, Praveen K; Patel, Anand; Hossain, Saamia et al. (2017) Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am J Clin Dermatol 18:1-15
Zloza, Andrew; Dharmadhikari, Neal D; Huelsmann, Erica J et al. (2017) Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. Cancer Immunol Immunother 66:9-16
Rehman, Hasan; Silk, Ann W; Kane, Michael P et al. (2016) Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer 4:53
Wisinski, Kari B; Tevaarwerk, Amye J; Burkard, Mark E et al. (2016) Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res 22:2659-67
Stein, Mark N; Hussain, Maha; Stadler, Walter M et al. (2016) A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer 14:22-7
Santanam, Urmila; Banach-Petrosky, Whitney; Abate-Shen, Cory et al. (2016) Atg7 cooperates with Pten loss to drive prostate cancer tumor growth. Genes Dev 30:399-407
West, Howard Jack; Jin, Jill O (2015) JAMA Oncology Patient Page. Circulating Tumor Cells. JAMA Oncol 1:394